Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial by CNBC Markets | February 23, 2026 3:44 pm | US Markets Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.
